Al­ny­lam up­dates its pitch for ex­pand­ed On­pat­tro la­bel with 18-month PhI­II da­ta

Al­ny­lam Phar­ma­ceu­ti­cals is so pleased with 18-month da­ta from its Phase III tri­al in­ves­ti­gat­ing On­pat­tro as a treat­ment of AT­TR car­diomy­opa­thy that it

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.